El gráfico muestra una selección de drogas existentes que podrían combatir el Covid-19.


Búsqueda de una droga para combatir el coronavirus

By Duncan Mil

March 30, 2020 - Médicos en todo el mundo realizan pruebas de readaptación de tratamientos farmacológicos para otras enfermedades – desde ébola hasta malaria pasando por artritis – en una carrera para ofrecer esperanza a pacientes de Covid-19.

Scientists are investigating three main types of medications in their quest to stop the pandemic. The first category includes antivirals to stop the virus from replicating. Treatments include the HIV drug combination Kaletra, which U.S. biotech AbbVie recently waived its patents on so it can be made available as a generic. Other therapies include the antimalarial drug chloroquine and an anti-flu drug from Japan’s Fujifilm.

Gilead Sciences’ Ebola drug, remdesivir, is also being repurposed to see if it can effectively treat COVID-19.

Second are anti-inflammatories that treat the lungs after the immune system is overwhelmed. Regeneron and Sanofi have partnered on Kevzara, while Roche has started a trial on Actemra, approved for use on rheumatoid arthritis in 100 countries.

The third category is antibody-based treatments, derived from recovered Covid-19 patients. Eli Lilly and Canadian start-up AbCellera are developing an antibody-based treatment, while Japan’s Takeda is developing a new drug derived from the blood plasma of others who have survived the virus.

Researchers at the University of Minnesota have launched clinical trials using the generic blood-pressure medication losartan.

In Australia, the bacillus Calmette-Guerin -- or BCG vaccine which has been used for a century to prevent tuberculosis -- is being given to 4,000 health-care workers in Melbourne to see if it will protect them against the coronavirus. Similar research is going on in the Netherlands, according to the EU Clinical Trials Register.

PUBLISHED: 30/03/2020; STORY: Graphic News
Graphic News Standards